LETTERS TO THE EDITORS

New insights into cortisol levels in PTSD


The article “Relationship of cortisol, norepinephrine, and epinephrine levels with war-induced posttraumatic stress disorder in fathers and their offspring” by Yahyavi et al.1 provided interesting data on the neuroendocrinology of post-traumatic stress disorder (PTSD). The mechanisms that underlie the associations of cortisol levels with traumatic exposures and PTSD are still not well understood and, as stated by the authors, findings are far from consistent.

Similarly to the findings of Yahyavi et al., in a sample of individuals exposed to trauma during the preceding 5 years, patients with PTSD had neither an increase nor a decrease in mean urinary cortisol levels.2 Conversely, in a recently published study, Wingenfeld et al.3 reported decreased cortisol values in outpatients with PTSD recruited from two Veterans Affairs medical centers. Furthermore, researchers have reported lower cortisol levels in the acute aftermath of trauma in patients who later developed PTSD.4

It seems that inadequate glucocorticoid release following stress not only delays recovery by disrupting biological homeostasis in the short run but can also interfere with the processing or interpretation of stressful information, resulting in long-term disruptions in memory integration.5 Consistent with these findings is the fact that a single dose of hydrocortisone administered in the acute aftermath of trauma produced recovery while promoting enhanced synaptic plasticity and connectivity in the secondary prevention of PTSD.6 In this sense, it remains unclear whether deregulation of the HPA axis, leading to low peritraumatic levels of cortisol, endures post-traumatically.

Another critical issue in this matter has to do with changes in cortisol levels secondary to pharmacological treatment of PTSD (e.g., sertraline), an important aspect not addressed by the authors.7 Finally, it is worth mentioning that PTSD is characterized by the presence of four symptom clusters (intrusion, avoidance, negative alterations in cognitions and mood, and alterations in arousal and reactivity) instead of the three mentioned in the paper.

Gabriela de Moraes Costa
Departamento de Neuropsiquiatria, Universidade Federal de Santa Maria (UFSM), Santa Maria, RS, Brazil


Disclosure

The author reports no conflicts of interest.

References


Clozapine-induced esophagitis at therapeutic dose: a case report


The pharmacological profile of clozapine, which is often described as a “broad spectrum” antagonist, is different from that of other antipsychotics. It is thought that the side effects reported with clozapine may be attributed in part to its anti-serotonin action together with its anti-α-adrenergic, anticholinergic, and antihistaminic effects.1

A 58-year-old chronic schizophrenic patient had been treated with haloperidol for over 10 years. Haloperidol was eventually replaced with a combination of antipsychotics (olanzapine/zuclopenthixol and later aripiprazole/ zuclopenthixol). Given the persistence of major psychotic symptoms, clozapine was gradually introduced in combination with the following treatments: aripiprazole (10 mg/d), zopiclone (7.5 mg/day, as needed), tropatepine (15 mg/day), and lorazepam (7.5 mg/d). During the first month of treatment, the dose of clozapine was gradually increased to 275 mg/d (at the end of 1 month). However, various side effects were observed, leading to the increase in tropatepine (30 mg/d) for extrapyramidal side effects and to the introduction of macrocrol 4,000 (30 g/d) for constipation, heptaminol (563.4 mg/d) for orthostatic hypotension, and paracetamol (3 to 4 g/d) for headaches.

After a second month of treatment the patient continued to describe somatic complaints, including nausea. Aripiprazole was stopped, and tropatepine was gradually reduced to 10 mg/d. In the meantime, clozapine was gradually increased based on good hematologic

References


The pharmacological profile of clozapine, which is often described as a “broad spectrum” antagonist, is different from that of other antipsychotics. It is thought that the side effects reported with clozapine may be attributed in part to its anti-serotonin action together with its anti-α-adrenergic, anticholinergic, and antihistaminic effects.1

A 58-year-old chronic schizophrenic patient had been treated with haloperidol for over 10 years. Haloperidol was eventually replaced with a combination of antipsychotics (olanzapine/zuclopenthixol and later aripiprazole/ zuclopenthixol). Given the persistence of major psychotic symptoms, clozapine was gradually introduced in combination with the following treatments: aripiprazole (10 mg/d), zopiclone (7.5 mg/day, as needed), tropatepine (15 mg/day), and lorazepam (7.5 mg/d). During the first month of treatment, the dose of clozapine was gradually increased to 275 mg/d (at the end of 1 month). However, various side effects were observed, leading to the increase in tropatepine (30 mg/d) for extrapyramidal side effects and to the introduction of macrocrol 4,000 (30 g/d) for constipation, heptaminol (563.4 mg/d) for orthostatic hypotension, and paracetamol (3 to 4 g/d) for headaches.

After a second month of treatment the patient continued to describe somatic complaints, including nausea. Aripiprazole was stopped, and tropatepine was gradually reduced to 10 mg/d. In the meantime, clozapine was gradually increased based on good hematologic
tolerance since the start of treatment. Nefopam was also introduced for the management of hemorrhoid pain as needed, at 20 mg/d (po). After an additional 35 days of treatment with clozapine at 350 mg/d, one night the patient had hematemesis and diffuse abdominal pain. The next morning, she experienced vomiting and complained of epigastric pain. The patient was treated with domperidone (30 mg/d) and metoclopramide (20 mg/d, po, as needed). Clinical examination revealed reflux esophagitis (grade 4) associated with a hiatal hernia (4 cm). A blood test showed plasma clozapine levels of 980 µg/l (laboratory alert level is plasma concentration > 1,000 µg/L).2 In this context, pantoprazole was introduced at a dosage of 20 mg/d, whereas domperidone was stopped after 1 week. Clozapine was gradually reduced to 200 mg/d. After 15 days, gastroesophageal symptoms had diminished and clozapine levels had fallen to 633 µg/L (therapeutic reference range = 350-600 µg/L).2 About 2 months after esophagitis, a gastroscopic control was performed, demonstrating complete esophageal healing. Table 1 synthesizes the clozapine dose changes following intoxication along with the plasma levels of clozapine.

Some disorders affecting the gastrointestinal tract, including cases of esophagitis with hiatal hernias, have been reported with the use of clozapine, but very few have been published.3 These gastrointestinal disturbances appear in connection with hypomotility and changes in digestive secretion induced by clozapine, as a result of its antiserotoninergic and anticholinergic properties.3 Anticholinergic medications are often implicated in exacerbating gastroesophageal reflux disease by decreasing lower esophageal sphincter pressure and consequently causing or aggravating heartburn, but such conditions were not identified in our patient before the occurrence of esophagitis.

In our patient, the combined use of clozapine, tropatepine, and aripiprazole (stopped a week before the adverse effect but with a long half-life) may have enhanced the effects of clozapine by contributing to anticholinergic and antiserotoninergic effects respectively (nefopam was only administered on 2 days: 4 and 24 days before esophagitis). However, the dramatic increase in clozapine blood concentration seems sufficient to account for the adverse effect. To the best of our knowledge, this is the first case of clozapine-induced severe esophagitis correlated to a measured-level of plasma clozapine to be published in the literature.

Hervé Javelot,1 Bruno Michel,2 Divya Kumar,3 Brigitte Audibert3

1 Clinical Pharmacy Service, Mental Health Establishment (EPSAN), Brumath, France. 2 Faculté de Pharmacie, Laboratoire HuManiS (EA 7308), Service Pharmacie - CHU de Strasbourg, Strasbourg, France. 3 Service G06, EPSAN, Brumath, France

Submitted Jul 31 2015, accepted Nov 09 2015.

Disclosure

The authors report no conflicts of interest.

References


Circadian rhythm disturbances and conversion to psychosis in ultra high-risk youth


Our group has recently showed that individuals in at risk mental states for psychosis and bipolar disorder (BD) have a poorer quality of sleep, start their daily activity later, and have a fragmented circadian rhythm compared with age and gender-matched healthy controls.1,2 Another study shows that adolescents at high risk of developing psychosis are more prone to nocturnal awakening, which reduces sleep efficiency.3 Nevertheless, the relationship

Table 1 Summary of changes on dosage and plasma clozapine levels following clozapine intoxication with available leucocyte and platelet counts

<table>
<thead>
<tr>
<th>Days</th>
<th>Clozapine dose (mg/day)</th>
<th>Clozapine level (µg/l) (n = 350-600 µg/l)*</th>
<th>Leukocyte count (x 10^9/L)</th>
<th>Platelet count (x 10^3/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>D1 - Day before blood collection</td>
<td>350</td>
<td>980</td>
<td>10.1</td>
<td>235</td>
</tr>
<tr>
<td>D2</td>
<td>-</td>
<td>-</td>
<td>11.2</td>
<td>236</td>
</tr>
<tr>
<td>D3 - Upper gastrointestinal endoscopy: grade 4 reflux esophagitis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D11</td>
<td>-</td>
<td>-</td>
<td>9.4</td>
<td>503</td>
</tr>
<tr>
<td>D17</td>
<td>250</td>
<td>633</td>
<td>6.9</td>
<td>481</td>
</tr>
<tr>
<td>D36</td>
<td>200</td>
<td>238</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>D43</td>
<td>200</td>
<td>192</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>D67 - Upper gastrointestinal endoscopy: fully healed esophagus</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D77</td>
<td>250</td>
<td>270</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>D84</td>
<td>250</td>
<td>263</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Letters to the Editors 177